Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors -: a single centre study

被引:27
作者
Remberger, M. [1 ]
Mattsson, J.
Hassan, Z.
Karlsson, N.
LeBlanc, K.
Omazic, B.
Okas, M.
Sairafi, D.
Ringden, O.
机构
[1] Karolinska Univ Hosp, Dept Clin Immunol, Karolinska Inst, SE-14186 Stockholm, Sweden
关键词
acute GVHD; RIC; URD; HSCT; risk factors;
D O I
10.1038/sj.bmt.1705913
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We analysed factors associated with moderate to severe acute GVHD in 111 patients treated with fludarabin-based reduced intensity conditioning ( RIC) and allogeneic haematopoietic stem cell transplantation ( HSCT). Most patients had a haematological malignancy. Donors were 97 HLA-A, -B and -DR beta 1 identical unrelated and 14 HLA-A, -B or -DR beta 1 allele mismatched unrelated donors. In the univariate analysis, we found ten factors associated with acute GVHD. These were diagnosis ( P=0.06), GVHD prophylaxis with combinations other than CsA+MTX ( P=0.006), graft nucleated ( P<0.001) and CD34 ( P<0.001) cell-dose, bidirectional ABO mismatch ( P=0.001), conditioning ( P=0.002), hospital vs home-care ( P=0.06), ATG dose ( P<0.001), donor herpes virus serology ( P=0.07) and an immunized female donor to male recipient ( P=0.05). In the multivariate analysis, three factors remained significant: a high CD34 cell dose ( P<0.001), low dose ( 4 mg/ kg) ATG ( P<0.001), and an immunized female donor to male recipient ( P<0.01). Patients receiving a CD34 cell dose >= 17.0 x 10(6) per kg had a higher incidence of GVHD, 53.7%, compared to 22.3% in patients receiving a lower dose ( P=0.002). In patients without any of these risk factors ( n=70), the incidence of acute GVHD was 14.1%, while it was 38.0 and 85.0% in patients with one ( n=29) or two ( n=10) risk factors ( P<0.001). We concluded that risk factors for acute GVHD using RIC are similar as using myeloablative conditioning.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 47 条
[1]  
ATKINSON K, 1990, BLOOD, V75, P2459
[2]   ABO COMPATIBILITY AND ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BACIGALUPO, A ;
VANLINT, MT ;
OCCHINI, D ;
MARGIOCCO, M ;
FERRARI, G ;
PITTALUGA, PA ;
FRASSONI, F ;
PERALVO, J ;
LERCARI, G ;
CARUBIA, F ;
MARMONT, AM .
TRANSPLANTATION, 1988, 45 (06) :1091-1094
[3]   Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) [J].
Bacigalupo, A ;
Lamparelli, T ;
Bruzzi, P ;
Guidi, S ;
Alessandrino, PE ;
di Bartolomeo, P ;
Oneto, R ;
Bruno, B ;
Barbanti, M ;
Sacchi, N ;
Van Lint, MT ;
Bosi, A .
BLOOD, 2001, 98 (10) :2942-2947
[4]   Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group [J].
Basara, N ;
Baurmann, H ;
Kolbe, K ;
Yaman, A ;
Labopin, M ;
Burchardt, A ;
Huber, C ;
Fauser, AA ;
Schwerdtfeger, R .
BONE MARROW TRANSPLANTATION, 2005, 35 (10) :1011-1018
[5]   Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications [J].
Beelen, DW ;
Trenschel, R ;
Casper, J ;
Freund, M ;
Hilger, RA ;
Scheulen, ME ;
Basara, N ;
Fauser, AA ;
Hertenstein, B ;
Mylius, HA ;
Baumgart, J ;
Pichlmeier, U ;
Hahn, JR ;
Holler, E .
BONE MARROW TRANSPLANTATION, 2005, 35 (03) :233-241
[6]  
BRENNER MK, 1986, HAEMATOLOGIA, V19, P167
[7]   The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia [J].
Byrne, JL ;
Stainer, C ;
Cull, G ;
Haynes, AP ;
Bessell, EM ;
Hale, G ;
Waldmann, H ;
Russell, NH .
BONE MARROW TRANSPLANTATION, 2000, 25 (04) :411-417
[8]   Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients:: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection [J].
Canals, C ;
Martino, R ;
Sureda, A ;
Altés, A ;
Briones, J ;
Subirá, M ;
Ancín, I ;
Martín-Henao, G ;
Brunet, S ;
Sierra, J .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (11) :1039-1043
[9]   Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia [J].
Carlens, S ;
Aschan, J ;
Remberger, M ;
Dilber, MS ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 1999, 24 (06) :629-635
[10]   Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT:: a matched pair analysis [J].
Duggan, P ;
Booth, K ;
Chaudhry, A ;
Stewart, D ;
Ruether, JD ;
Glück, S ;
Morris, D ;
Brown, CB ;
Herbut, B ;
Coppes, M ;
Anderson, R ;
Wolff, J ;
Egeler, M ;
Desai, S ;
Turner, AR ;
Larratt, L ;
Gyonyor, E ;
Russell, JA .
BONE MARROW TRANSPLANTATION, 2002, 30 (10) :681-686